154 related articles for article (PubMed ID: 34267040)
1. [Pneumothorax during Pazopanib Therapy in a Patient with Soft Tissue Sarcoma].
Kanno N; Nakahashi K; Shiikawa M; Endo M; Numahata K; Shiono S
Gan To Kagaku Ryoho; 2021 Jul; 48(7):975-977. PubMed ID: 34267040
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?].
Agrafiotis AC; Prieto M; Verhaeghe JL; Siat J; Grosdidier G; Rios M
Rev Pneumol Clin; 2016 Oct; 72(5):293-295. PubMed ID: 27561973
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
Harada Y; Kakimoto S; Shimizu T
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32641305
[TBL] [Abstract][Full Text] [Related]
4. Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.
Aiba H; Kimura H; Yamada S; Okamoto H; Hayashi K; Miwa S; Kawaguchi Y; Saito S; Sakai T; Tatematsu T; Nakanishi R; Murakami H
PLoS One; 2021; 16(7):e0254866. PubMed ID: 34270626
[TBL] [Abstract][Full Text] [Related]
5. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
6. Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
Sabath B; Muhammad HA; Balagani A; Ost DE; Vakil E; Ahmed T; Vial MR; Grosu HB
BMC Cancer; 2018 Oct; 18(1):937. PubMed ID: 30285733
[TBL] [Abstract][Full Text] [Related]
7. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series.
Verschoor AJ; Gelderblom H
Clin Sarcoma Res; 2014; 4():14. PubMed ID: 25302110
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
Karaağaç M; Eryılmaz MK
J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib and soft-tissue sarcomas. Too toxic.
Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
[TBL] [Abstract][Full Text] [Related]
10. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
[TBL] [Abstract][Full Text] [Related]
11. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Pazopanib on the Cardiovascular System.
Justice CN; Derbala MH; Baich TM; Kempton AN; Guo AS; Ho TH; Smith SA
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):387-398. PubMed ID: 29706106
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Tardy C; Puszkiel A; Boudou-Rouquette P; De Percin S; Alexandre J; Berge M; Ulmann G; Blanchet B; Batista R; Goldwasser F; Thomas Schoemann A
Cancer Chemother Pharmacol; 2024 Feb; 93(2):169-175. PubMed ID: 37620675
[TBL] [Abstract][Full Text] [Related]
14. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report.
Puliafito I; Russo A; Sciacca D; Puglisi C; Giuffrida D
J Med Case Rep; 2020 Jan; 14(1):7. PubMed ID: 31924259
[TBL] [Abstract][Full Text] [Related]
17. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
Gennigens C; Jerusalem G
Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
[TBL] [Abstract][Full Text] [Related]
18. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.
Westerdijk K; Krens SD; Steeghs N; van der Graaf WTA; Tjwa ETTL; Westdorp H; Desar IME; van Erp NP
Cancer Chemother Pharmacol; 2024 Apr; 93(4):353-364. PubMed ID: 38104304
[TBL] [Abstract][Full Text] [Related]
19. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
[No Abstract] [Full Text] [Related]
20. Pazopanib-induced enteritis in a patient with renal cell carcinoma.
Ariyoshi M; Hayashi R; Takasago T; Yamashita K; Hiyama Y; Yuge R; Urabe Y; Ueno Y; Shimamoto F; Oka S
Clin J Gastroenterol; 2024 Jun; 17(3):434-440. PubMed ID: 38407743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]